National HealthCare stock
NHCAMEXNational HealthCare Corporation, HealthcareISIN US6359061008
68Score 68 out of 100, Neutral
Price and trend
55 / 100
Price history
+59% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 6.9% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 24).
The price is 15% below its 52-week high. Largest decline in 20 years: 47% (February 2007 to August 2011).
Chart figures for advanced users
- SMA 50$223.43
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$196.76
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)24
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$124.93
- The lowest closing price of the last twelve months.
- Resistance$247.94
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- National HealthCare Corporation belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $3.3B, is number 23 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.52B (up 16.9% year on year) and earnings of $120.02M (up 17.7%).
- MEQIRI Score 68 out of 100 (Neutral): rank 173 of 714 in Healthcare, median 53.
Show more
- The P/E is 29.3 (Medical (Care Facilities) median 19.4, own median of recent years 19.8).
- Our model puts fair value at $292.75, with the price 28% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 23.1% a year since 2020.Growth 66
- Reliable dividendNo dividend cut for 22 years.Capital allocation 60
- Earnings turn into cashFree cash flow 153% of earnings over the last 12 months.Fundamentals 88
Weaknesses
- Richly valuedP/E 29.3, Medical (Care Facilities) median 19.4, own median 19.8.Valuation 67
Its standout strengths are fundamentals and stability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 69 to 68.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $209.11 and expensive above $487.92 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $446.46 (cash-flow model) and $139.05 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $253.34, at 7.8% it would be $352.03.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 5.6% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 39%, operating 8%, net 8%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- No date announced.
- Last reported
- 6 Nov 2026EPS reported $0.87
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $174,859 in total. 9 insiders sold, $8.91M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Dodson Vicki LSale
22 Sept 2026, Sr.VP Patient Srvcs
- Shares
- 4,834
- Price
- $225.00
- Value
- $1.09M
- Kidd Brian FSale
11 Sept 2026, SVP, CFO
- Shares
- 6,813
- Price
- $225.70
- Value
- $1.54M
- McCreary Josh ASale
10 Sept 2026, Senior VP & General Counsel
- Shares
- 2,719
- Price
- $224.23
- Value
- $609,669
Show 14 more
- Flatt Ben Anderson SrSale
28 Aug 2026, Senior VP & CIO
- Shares
- 1,000
- Price
- $222.50
- Value
- $222,500
- Flatt Ben Anderson SrSale
25 Aug 2026, Senior VP & CIO
- Shares
- 1,000
- Price
- $227.00
- Value
- $227,000
- Gifford David R.Sale
25 Aug 2026, Board
- Shares
- 1,779
- Price
- $225.42
- Value
- $401,022
- Flatt Ben Anderson SrSale
20 Aug 2026, Senior VP & CIO
- Shares
- 1,000
- Price
- $237.00
- Value
- $237,000
- Flatt Ben Anderson SrSale
19 Aug 2026, Senior VP & CIO
- Shares
- 1,000
- Price
- $237.18
- Value
- $237,180
- Flatt Stephen FowlerSale
19 Aug 2026, CEO
- Shares
- 1,500
- Price
- $237.08
- Value
- $355,620
- Flatt Ben Anderson SrSale
17 Aug 2026, Senior VP & CIO
- Shares
- 1,000
- Price
- $226.00
- Value
- $226,000
- Flatt Ben Anderson SrSale
14 Aug 2026, Senior VP & CIO
- Shares
- 1,000
- Price
- $222.11
- Value
- $222,110
- Flatt Ben Anderson SrSale
12 Aug 2026, Senior VP & CIO
- Shares
- 1,000
- Price
- $221.21
- Value
- $221,210
- Hassan Emil ESale
22 Jun 2026, Board
- Shares
- 5,937
- Price
- $200.00
- Value
- $1.19M
- Hassan Emil ESale
16 Jun 2026, Board
- Shares
- 1,563
- Price
- $199.98
- Value
- $312,561
- Piercey LisaPurchase
1 Jun 2026, Board
- Shares
- 949
- Price
- $184.26
- Value
- $174,859
- Laroche Richard F JrSale
21 May 2026, Board
- Shares
- 7,500
- Price
- $195.14
- Value
- $1.46M
- Shelly Timothy J.Sale
19 May 2026, Sr.VP Operations
- Shares
- 1,853
- Price
- $197.22
- Value
- $365,444
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at National HealthCare
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Hims & Hers HealthHIMS $4.68B35
- MedicoverMCOV-B.ST $4.02B62
- Acadia HealthcareACHC $3.61B47
- Surgery PartnersSGRY $3.49B53
- Guardian Pharmacy ServicesGRDN $3.16B77
- Aveanna Healthcare HoldingsAVAH $2.86B63
- Ardent HealthARDT $2.56B60
- Pediatrix Medical GroupMD $2.46B70
ETFs that hold National HealthCare
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.20% | 0.30% | €185.82M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.15% | 0.30% | €2.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.09% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.09% | 0.30% | €4.22B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.03% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026, previously Strong
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.